{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:19:07Z","timestamp":1792293547244,"version":"4.4.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lutathera, a key therapy for gastroenteropancreatic neuroendocrine tumors, has demonstrated efficacy, but its real-world safety profile remains unclear. This study aims to conduct a comprehensive analysis of the adverse events (AEs) associated with Lutathera using FDA Adverse Event Reporting System (FAERS) data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>A retrospective pharmacovigilance analysis was conducted using FAERS data from Q4 2019 to Q3 2024. AE reports involving Lutathera were identified, and a case\/non-case approach was employed to evaluate AE signals using disproportionality analysis methods, including the reporting odds ratio and information component (IC). Patient demographics, time to AE onset, and system organ class (SOC) involvement were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>After data processing, a total of 4284 AE reports associated with Lutathera were analyzed. The median time to AE onset was 113.5 days. Lutathera-related AEs exhibited a notably high mortality rate, reaching as much as 31.2%. Statistically significant signals were detected across 13 SOCs and multiple preferred terms (PTs). Among the SOCs, the most pronounced signals were observed in the category of endocrine disorders. The leading PTs included nonspecific disorders (IC<jats:sub>025<\/jats:sub>: 5.92), carcinoid syndrome (IC<jats:sub>025<\/jats:sub>: 5.69), and carcinoid crisis (IC<jats:sub>025<\/jats:sub>: 5.62). Moreover, several PTs not documented in the drug\u2019s labeling were reported, such as encephalitis, intestinal ischemia, and disseminated intravascular coagulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our study utilized real-world data to identify multiple risk signals associated with Lutathera, providing additional evidence to support its rational use. However, due to the inherent limitations of the FAERS database, further research is warranted to validate these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005861","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:00:37Z","timestamp":1746100837000},"page":"714-720","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Post-marketing Safety Evaluation of Lutathera (177Lu-DOTATATE)"],"prefix":"10.1097","volume":"50","author":[{"given":"Heng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1949-1201","authenticated-orcid":false,"given":"Junlong","family":"Ma","sequence":"additional","affiliation":[{"name":"Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"R1-20250630","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250630","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"R3-20250630","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","article-title":"Consensus on molecular imaging and theranostics in neuroendocrine neoplasms","volume":"146","author":"Ambrosini","year":"2021","journal-title":"Eur J Cancer"},{"key":"R4-20250630","first-page":"47","article-title":"Peptide receptor radionuclide therapy: an overview","volume":"30","author":"Dash","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"R5-20250630","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-20250630","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20250630","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera(\u00ae): the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"R8-20250630","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177)Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"R9-20250630","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"R10-20250630","doi-asserted-by":"crossref","first-page":"1070497","DOI":"10.3389\/fmed.2022.1070497","article-title":"Commercial and business aspects of alpha radioligand therapeutics","volume":"9","author":"Ostuni","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R11-20250630","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20250630","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20250630","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R14-20250630","doi-asserted-by":"crossref","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"R15-20250630","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Song","year":"2023","journal-title":"Haematologica"},{"key":"R16-20250630","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s10194-024-01858-4","article-title":"Post-marketing safety concerns with rimegepant based on a pharmacovigilance study","volume":"25","author":"Hu","year":"2024","journal-title":"J Headache Pain"},{"key":"R17-20250630","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"R18-20250630","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","article-title":"Performance of probabilistic method to detect duplicate individual case safety reports","volume":"37","author":"Tregunno","year":"2014","journal-title":"Drug Saf"},{"key":"R19-20250630","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40264-022-01210-2","article-title":"Anti-tumor necrosis factor-alpha therapy and hypoglycemia: a real-world pharmacovigilance analysis","volume":"45","author":"Zhou","year":"2022","journal-title":"Drug Saf"},{"key":"R20-20250630","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2011.04009.x","article-title":"Memory disorders associated with consumption of drugs: updating through a case\/noncase study in the French PharmacoVigilance Database","volume":"72","author":"Chavant","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R21-20250630","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-200225010-00002","article-title":"Case-population studies in pharmacoepidemiology","volume":"25","author":"Capell\u00e0","year":"2002","journal-title":"Drug Saf"},{"key":"R22-20250630","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"key":"R23-20250630","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"R24-20250630","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","author":"Sabet","year":"2013","journal-title":"J Nucl Med"},{"key":"R25-20250630","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"R26-20250630","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.3390\/cancers14246022","article-title":"(177)Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: a joint analysis of phase II prospective clinical trials","volume":"14","author":"Bongiovanni","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R27-20250630","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.4103\/jcrt.JCRT_22_18","article-title":"Lutetium therapy-induced carcinoid crisis: a case report and review of literature","volume":"16","author":"Yadav","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R28-20250630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.03.002","article-title":"Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions","volume":"66","author":"Tapia Rico","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R29-20250630","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jcrc.2020.08.011","article-title":"Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): a case report","volume":"60","author":"Dhanani","year":"2020","journal-title":"J Crit Care"},{"key":"R30-20250630","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.soc.2020.08.001","article-title":"Surgical management of neuroendocrine tumor liver metastases","volume":"30","author":"Tran","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"key":"R31-20250630","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s13311-016-0433-7","article-title":"Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management","volume":"13","author":"Bradshaw","year":"2016","journal-title":"Neurotherapeutics"},{"key":"R32-20250630","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.preteyeres.2006.05.001","article-title":"Herpes simplex keratitis","volume":"25","author":"Kaye","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"R33-20250630","doi-asserted-by":"crossref","first-page":"e1002685","DOI":"10.1371\/journal.pmed.1002685","article-title":"Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study","volume":"15","author":"Warny","year":"2018","journal-title":"PLoS Med"},{"key":"R34-20250630","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.idc.2020.02.006","article-title":"Herpesvirus infections potentiated by biologics","volume":"34","author":"Ho","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"R35-20250630","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb Haemost"},{"key":"R36-20250630","doi-asserted-by":"crossref","first-page":"e27455","DOI":"10.1097\/MD.0000000000027455","article-title":"Hemorrhagic disseminated intravascular coagulation after 177Lu-Dotatate in metastatic midgut neuroendocrine tumor: a case report","volume":"100","author":"Worbe","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R37-20250630","first-page":"1","article-title":"Evidence of disseminated intravascular coagulation in a porcine model following radiation exposure","volume":"3","author":"Krigsfeld","year":"2014","journal-title":"Life Sci Space Res (Amst)"},{"key":"R38-20250630","doi-asserted-by":"crossref","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:01:38Z","timestamp":1751299298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005861"}},"subtitle":["A Pharmacovigilance Analysis of FDA Adverse Event Reporting System"],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005861","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2025-02-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}